[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333104-105":59,"doc-detail-333104-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","controlled-ovarian-stimulation-in-cancer-patients-under-18-years-old-case-series","Controlled ovarian stimulation in cancer patients under 18 years old - Case series","","Fertility preservation for adolescent pubescent girls with cancer raises major concerns for healthcare systems and families. Oocyte cryopreservation is commonly regarded as a standard option for patients aged at least 18, yet ovarian stimulation before 18 remains challenging and less well studied. This case series evaluates ovarian stimulation outcomes combined with oocyte cryopreservation and related approaches in younger patients prior to cancer treatment, describing results across multiple cancer diagnoses. Findings address feasibility while highlighting the need for acceptable fertilization rates and reported live births to support broader application.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/controlled-ovarian-stimulation-in-cancer-patients-under-18-years-old-case-series/333104/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/controlled-ovarian-stimulation-in-cancer-patients-under-18-years-old-case-series/333104.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is fertility preservation important for adolescent girls with cancer?","Question",{"text":112,"@type":113},"Cancer therapies can cause long-term gonadotoxic effects. Preserving future reproductive potential is therefore central to improving quality of life and maintaining the ability to have a biological child later.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What fertility preservation methods are discussed for pediatric and adolescent cancer patients?",{"text":117,"@type":113},"The document describes mature oocyte or embryo cryopreservation and ovarian tissue cryopreservation. Oocyte/embryo cryopreservation is presented as standard after adequate time for stimulation, while ovarian tissue cryopreservation is used when treatment cannot be delayed.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the case series report about ovarian stimulation outcomes under age 18?",{"text":121,"@type":113},"Oocyte cryopreservation was performed in seven patients with different cancers, embryo cryopreservation in one patient, and both oocyte and embryo cryopreservation in one patient. No oocytes were retrieved in a patient with medulloblastoma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},333104,1790219290,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Yahyaei etal. Journal of Ovarian Research (2024) 17:33  \n[https://doi.org/10.1186/s13048-024-01352-0](https://doi.org/10.1186/s13048-024-01352-0)  \nJournal of Ovarian Research  \n CASE REPORT Open Access  \nControlled ovarian stimulation in cancer patients under 18 years old; a case series  \nAzar Yahyaei1, Mahdieh Moridi 1 and Firouzeh Ghaffari1*  \nAbstract  \nBackground Fertility preservation for adolescent pubescent girls is a concern of the healthcare system and parents. Oocyte cryopreservation is regarded as a standard medical intervention for patients with a minimum age of 18 years. Evidence suggests that mature oocyte cryopreservation is possible for adolescent pubescent girls, although, ovarian stimulation for these patients remains a challenge.  \nCases presentation This case series is the first report regarding ovarian stimulation with oocyte cryopreservation in younger than 18 years cancerous girls, who refer to ROYAN institute, Tehran, Iran, prior to the start of the treatment of cancer (November 2015 to February 2021) . The oocyte cryopreservation was carried out in the 7 patients (five patients with Hodgkin lymphoma, one patient with Ewing sarcoma, and one patient with osteogenic tumor), the embryo cryopreservation in one patient with dysgerminoma, and the oocyte and embryo cryopreservation in one patient with germ cell tumor. No oocytes were retrieved after ovarian stimulation in the patient with medulloblastoma. For one of the patients with Hodgkin lymphoma, half of the tissues of one ovary were cryopreserved prior to ovarian stimulation.  \nConclusions Oocyte cryopreservation is a feasible option of fertility preservation in the adolescent’s patients  \nwith cancer. However, only if reported acceptable fertilization rates, as well as the successful cases of live birth  \nfrom oocyte cryopreservation at the ages under 18, this option of preserving fertility can be applied to this age range. Keywords Fertility preservation, Oocyte cryopreservation, Controlled ovarian stimulation, Cancer patients, Adolescent pubescent girls, Case series  \nBackground  \nAlthough the survival of children and adolescents with cancer has significantly increased in recent decades, cancer survivors suffer from long-term complications of this disease or its therapies, such as gonadotoxicity of therapies. The importance of enhancing this patient’s quality of life and preserving their ability to have a  \n*Correspondence: Firouzeh Ghaffari[ghafaryf@yahoo.com](ghafaryf@yahoo.com)  \n1 Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Number 12, East Hafez Avenue, Banihashem Street, Resalat Highway, Tehran, Iran  \nbiological child in the future life highlights the necessity of fertility preservation (FP) strategies. Preserving the fertility of adolescent pubescent girls is a hot topic of discussion [1, 2] .  \nThe main options for FP in cancer patients include mature oocyte, or embryo, and ovarian tissue cryopreservation (OTC). Mature oocyte or embryo cryopreservation (EC) is a standard FP method in post-pubescent women if they have had adequate time for ovarian stimulation (OS). OTC is a FP method for pre-pubescent girls and post-pubescent patients who cannot delay the onset of cancer treatment [3, 4]. Previously, it was considered experimental; however, the American Society for Reproductive Medicine (ASRM) proposed OTC as an established method [5]. Although pediatric research must  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Com","cbCailV5Rw1kPujz","https://ap.wps.com/l/cbCailV5Rw1kPujz","pdf",907020,"English","# Abstract\n# Background\n## Fertility preservation needs in adolescent cancer patients\n## Main fertility preservation options\n# Case presentation\n## Patients and cryopreservation outcomes\n# Conclusions\n## Feasibility and requirements for adoption","[{\"question\":\"Why is fertility preservation important for adolescent girls with cancer?\",\"answer\":\"Cancer therapies can cause long-term gonadotoxic effects. Preserving future reproductive potential is therefore central to improving quality of life and maintaining the ability to have a biological child later.\"},{\"question\":\"What fertility preservation methods are discussed for pediatric and adolescent cancer patients?\",\"answer\":\"The document describes mature oocyte or embryo cryopreservation and ovarian tissue cryopreservation. Oocyte/embryo cryopreservation is presented as standard after adequate time for stimulation, while ovarian tissue cryopreservation is used when treatment cannot be delayed.\"},{\"question\":\"What did the case series report about ovarian stimulation outcomes under age 18?\",\"answer\":\"Oocyte cryopreservation was performed in seven patients with different cancers, embryo cryopreservation in one patient, and both oocyte and embryo cryopreservation in one patient. No oocytes were retrieved in a patient with medulloblastoma.\"}]","Controlled ovarian stimulation in cancer patients under 18 years old - Case series | PDF",1790000864,25]